NICE rejects Erbitux in head and neck cancer

pharmafile | June 24, 2009 | News story | Research and Development, Sales and Marketing |  Erbitux, Merck Serono, NICE 

Related Content

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …

NICE recommends allergy immunotherapy tablets for younger children

NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …

NICE backs atogepant for acute migraine treatment

NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …

The Gateway to Local Adoption Series

Latest content


Five Facts about COPD

October 11, 2026